Introduction {#sec1}
============

The current number of *Chlamydia trachomatis* (*C. trachomatis*) infections diagnosed globally (\~127 million people/year; [@ref20]) is likely to be grossly underestimated as \~50% of male and 75% of female infections are asymptomatic ([@ref3]). These asymptomatic infections form an unrecognised chlamydial reservoir contributing to ongoing transmission in the community. The effect of asymptomatic infection on male fertility remains unclear ([@ref3]). Chlamydial infection has been associated with infertility in women, but much less is known about the impact of chlamydial infection on male fertility ([@ref3]).

Male factors account for \~40% of human infertility; most are described as idiopathic but with genetic and environmental factors also proposed ([@ref8]). In the absence of a known pathological process, a descriptive approach is applied clinically, based on abnormalities of sperm number, motility and/or morphology (a surrogate marker of function) identified by semen analysis ([@ref19]). Excluding obstructive azoospermia, changes in sperm number, motility and/or morphology are thought to reflect dysfunctional spermatogenesis which occurs in the seminiferous tubules, within which germ cell replication and development proceeds in close association with the supporting Sertoli cells. Testicular histological patterns range from Sertoli cell only appearance, arrested germ cell development or a reduction in all germ cell populations, termed hypospermatogenesis ([@ref11]). Each pattern can arise from a range of insults including genetic, infectious or toxic exposure.

Infectious diseases, such as mumps virus infection of the human testis, are known to play a role in spermatogenic dysfunction and have been associated with abnormal sperm parameters ([@ref10]). Bacteria including *E. coli*, mycoplasmas and *C. trachomatis* in human semen are also associated with abnormal sperm parameters ([@ref5]; [@ref12]). Yet there are no consistent histological indicators or markers observed during semen analysis for male infertility associated with chlamydial infection in humans. However, a mouse model demonstrated that chlamydial infection impairs testicular health and reduces sperm motility and normal morphology ([@ref17]).

Challenges in attributing male infertility to chlamydial infection include the wide diversity in diagnostic approaches ([@ref16]). Options for the diagnosis of *C. trachomatis* infection include detection of *Chlamydia*-specific antibodies (which may not be *C. trachomatis*-specific or discriminate between current versus previous infection), culture (which is rarely used clinically), immunofluorescent detection of *Chlamydia* within urine, semen or urethral swab and PCR amplification of chlamydial DNA from urine, semen or urethral swab ([@ref16]). Conventionally, first-void urine testing by PCR is used, yet this may not be sensitive enough to detect chronic or asymptomatic infections in the testis ([@ref16]). Testing of semen may be more sensitive, with detection being reported when urine testing is negative and in semen donated for artificial insemination ([@ref6]; [@ref18]; [@ref21]; [@ref15]; [@ref4]). This suggests that the upper reproductive tract may be a source of sexually transmissible *Chlamydia* that is undetected by the current nucleic acid amplification test (NAAT), and this requires further investigation.

We sought to establish whether testicular infection is associated with impaired spermatogenesis and male infertility by examining human testicular biopsies of men presenting with idiopathic nonobstructive azoospermia (NOA). Tissue was obtained from men presenting for testicular sperm extraction for use in intracytoplasmic sperm injection treatment and from men undergoing testicular biopsy for diagnostic evaluation of fertility.

Materials and Methods {#sec2}
=====================

Ethics {#sec3}
------

Bouin's fixed biopsies were collected under ethical approval given by Monash University (UHREC: RES-16-0000-559L) and Queensland University of Technology (QUT, UHREC: 1700000362). Fresh biopsies were collected under ethical approval given by Epworth (HREC: 666-15), Monash Health (HREC: 15489M), Queensland Fertility Group (QFG) (HREC: QFG12.15) and Queensland University of Technology (QUT) (UHREC: 1500000394) after patients provided signed patient informed consent forms.

Tissue collection {#sec4}
-----------------

Bouin's fixed, paraffin-embedded testicular biopsies (*n* = 100) were obtained from Monash Health Anatomical Pathology Department. Subjects were selected by the clinical note of 'azoospermia' and absence of defined causes for spermatogenic failure (e.g. Klinefelter syndrome, prior chemoradiotherapy, testicular infarction or trauma) and thus were presumed idiopathic NOA. Samples were deidentified (now MB001 to MB100).

Additionally, deidentified fresh testicular biopsies (*n* = 18) were obtained by microdissection testicular sperm extraction (micro-TESE) and testicular sperm aspiration biopsy (TESA), from patients attending Monash IVF Group (Melbourne) and QFG for assisted reproductive technology (ART) procedures. In contrast with the fixed biopsies, this cohort contained samples from patients with both known and unknown causes of infertility (e.g. cystic fibrosis, Klinefelter syndrome, chemotherapy and azoospermia). These were sent to QUT for analysis. These patients also answered a survey on previous diagnosis of sexually transmitted infections (STIs).

Fixed biopsy immunohistochemistry {#sec5}
---------------------------------

Two chlamydial markers were detected: the general marker major outer membrane protein (MOMP) and the active replication marker TC0500 ([@ref13]). Sections (4 μm) were dewaxed and rehydrated (Leica ST5010-CV5030 Integrated Workstation). Endogenous peroxidase activity was quenched (2% H~2~O~2~). Antigen retrieval was performed (Diva Decloaker, Biocare Medical, CA, USA) as per the manufacturer's instructions. Nonspecific binding was blocked (2% BSA in Background Sniper, Biocare Medical). The primary anti-MOMP IgG (raised in sheep) or primary anti-TC0500 IgG (mouse derived hybridoma: generated by the Monoclonal Antibody Technologies Facility, Monash University, Australia) was applied at room temperature. The primary antibody was then washed off and followed with anti-sheep or anti-mouse IgG-HRP. The secondary antibody was washed off and followed with DAB chromogen. Finally, sections were counterstained using haematoxylin (Leica XL Autostainer). Staining was validated using primary antibody only, secondary antibody only and DAB only controls. Stained slides were scanned (Aperio AT Turbo, Leica Biosystems). Positive staining was determined by four individuals, by the presence of chlamydial inclusions, which stained brown-black. Staining was conducted in collaboration with QIMR Berghofer Histology Services. A chi-squared test statistic was applied to MOMP staining results.

DNA extraction from biopsies {#sec6}
----------------------------

QIAamp DNA FFPE Tissue Kit (56404, Qiagen, VIC, Australia) was used to extract DNA from fixed biopsies. DNA was extracted from fresh biopsies using DNeasy Blood and Tissue kit (69506, Qiagen). DNA was extracted from *C. trachomatis* serovar D (ATCC® VR-855™) as a positive control. Kits were used as per the manufacturer's instructions.

Chlamydial real-time PCR {#sec7}
------------------------

*C. trachomatis* 16S rRNA DNA was detected using real-time PCR (RG6000, Qiagen). Primers were 5′-GCGAAGGCGCTTTTCTAATTTAT-3′ (forward) and 5′-CCAGGGTATCTAATCCTGTTTGCT-3′ (reverse). Amplification conditions included 95°C for 10 min, 40 cycles of 95°C for 30 s, 52°C for 30 s, 74°C for 30 s, then 74°C for 2 min before standard melt analysis. Amplicons were confirmed as chlamydial in origin when they melted within 4°C of the positive control. Amplicons were electrophoresed on 2% agarose gel for size comparison.

*C. trachomatis*-specific antibodies {#sec8}
------------------------------------

Serum samples matched to fresh biopsies were assayed for *C. trachomatis*-specific antibodies. *C. trachomatis* serovars D and E (20 μg/drop) were spotted onto nitrocellulose membranes. Membranes were probed with the serum samples (diluted 1:100), then with anti-human IgG-HRP (Southern Biotech), then developed and viewed with enhanced chemiluminescence (GE Healthcare). Additionally, HeLa cell monolayers were infected with *C. trachomatis* serovar D for 48 h, fixed (100% methanol), then probed with serum to detect *C. trachomatis*-specific antibodies, followed by anti-human IgG-AF594 (diluted 1:1000, Thermo Fisher Scientific). Stained cells were viewed using epifluorescent microscopy (Zeiss, Axio Vert.A1).

###### 

Chlamydial MOMP positivity rate in fixed human testicular biopsies.

  **Histological pattern**              **Number with MOMP positivity (%)**
  ------------------------------------- -------------------------------------
  Sertoli cell only appearance          21/51 (41.2%)
  Germ cell arrest                      6/11 (54.5%)
  Combined hypospermatogenesis groups   15/33 (45.5%)
  • Mild hypospermatogenesis            7/16 (43.7%)
  • Moderate hypospermatogenesis        2/5 (40.0%)
  • Marked/severe hypospermatogenesis   6/12 (50.0%)
  Combined total                        43/95 (45.3%)

*n* = 95; 5 of the 100 samples were eliminated due to insufficient tissue. MOMP, major outer membrane protein.

Results {#sec9}
=======

Actively replicating *Chlamydia* detected in testicular biopsies {#sec10}
----------------------------------------------------------------

Of the 100 fixed biopsies, five were eliminated due to insufficient tissue. Sections were probed for MOMP ([Fig. 1](#f1){ref-type="fig"}a--c) and TC0500 ([Fig. 1](#f1){ref-type="fig"}d--f). Staining controls (primary or secondary antibody only, and DAB only) each showed little or no positive staining, thereby validating the localisation patterns shown ([Supplementary Fig. S1](#sup1){ref-type="supplementary-material"}).

![**Histological detection of *Chlamydia* in human testicular biopsies.** Tissues were provided by Monash Health Anatomical Pathology Department and stained using immunohistochemistry techniques for chlamydial major outer membrane protein (MOMP, **a**--**c**) and the active replication marker TC0500 (DAB chromogen, dark brown, **d**--**f**) then counterstained to show tissue structure (haematoxylin, blue). Panels (a) and (d) noninfected testicular tissue (patient code MB020), (b) and (e) *Chlamydia* identified in interstitial human testicular tissue (patient code MB058) and (c) and (f) *Chlamydia* identified in seminiferous tubules of human testicular tissue (patient code MB036). Scale bars represent 200 μm; images are representative of *n* = 5 noninfected and *n* = 5 infected samples; images were captured on ×20 magnification.](dez169f1){#f1}

![**Detection of *C. trachomatis* DNA in fixed testicular biopsies from male-factor infertility patients.** Tissues were provided by Monash Health Anatomical Pathology Department, DNA was extracted from tissue sections (Qiagen FFPE DNA kit) and real-time PCR specific to *C. trachomatis* 16S rRNA DNA was performed. Amplicons were electrophoresed on agarose gel to obtain the representative image pictured, which includes *C. trachomatis* serovar D (Ctr D) positive control and several positive (MB049, MB015, MB029, MB047, MB095, MB018, MB046) and negative (MB051, MB041, MB057) samples. The molecular weight (MW) marker shows the amplicon size to be \<100 bp.](dez169f2){#f2}

![**Detection of *C. trachomatis* DNA in fresh testicular biopsies from male-factor infertility patients.** Testicular biopsies were provided by Monash IVF Group and Queensland Fertility Group, DNA was extracted from tissue (QIAmp Blood and Tissue kit) and real-time PCR specific to *C. trachomatis* 16S rRNA DNA was performed. Amplicons were electrophoresed agarose gel to obtain the representative image pictured, which includes positive (Patient 1, 4 and 5) and negative (Patient 2 and 3) samples. The positive control used was *C. trachomatis* serovar D DNA. The molecular weight (MW) marker shows the amplicon size to be \<100 bp.](dez169f3){#f3}

Chlamydial MOMP was detected in 43 of 95 samples, equating to a 45.3% rate of infection overall. When categorised by histological pattern, the rate of infection ranged from 40 to 54% ([Table I](#TB1){ref-type="table"}). No significant difference (*P* = 0.1) was found in infection rates between histological categorisations.

A range of MOMP positive (*n* = 11) and negative (*n* = 9) sections were selected where sufficient tissue was available. These were stained to detect the active replication marker TC0500. Positive TC0500 staining was observed in all MOMP-positive sections, indicating that *Chlamydia* was actively replicating within the testes at the time of biopsy. There was a 100% concordance between MOMP and TC0500 staining ([Table II](#TB2){ref-type="table"}).

Confirmation of positive staining was achieved *via C. trachomatis* 16S rRNA-specific PCR on DNA extracted from the fixed biopsies ([Fig. 2](#f2){ref-type="fig"}). A range of MOMP-positive (*n* = 8) and negative (*n* = 8) samples were selected where sufficient tissue was available. *C. trachomatis* DNA was detected in 100% of MOMP-positive samples ([Table II](#TB2){ref-type="table"}). There was a 100% concordance between immunohistochemistry and PCR techniques for MOMP-positive samples. For MOMP-negative samples, there was a 50% concordance between immunohistochemistry and PCR techniques as four of eight samples returned *C. trachomatis*-positive PCR results. A representative gel electrophoresis image of PCR-positive and -negative samples is shown ([Fig. 2](#f2){ref-type="fig"}).

###### 

Concordance between chlamydial immunohistochemistry markers and PCR in selected fixed samples.

  **Sample identifier**   **MOMP**   **TC0500**   **PCR**
  ----------------------- ---------- ------------ ---------
  MB049                   \+         \+           \+
  MB015                   \+         \+           \+
  MB029                   \+         \+           \+
  MB095                   \+         \+           \+
  MB018                   \+         \+           \+
  MB014                   \+         \+           \+
  MB060                   \+         \+           \+
  MB045                   \+         N/A          \+
  MB028                   \+         \+           N/A
  MB096                   \+         \+           N/A
  MB058                   \+         \+           N/A
  MB036                   \+         \+           N/A
  MB039                   \_         \_           \+
  MB047                   \_         \_           \+
  MB046                   \_         \_           \+
  MB052                   \_         N/A          \+
  MB085                   \_         N/A          \_
  MB051                   \_         \_           \_
  MB041                   \_         \_           \_
  MB057                   \_         \_           \_
  MB075                   \_         \_           N/A

Detection of *C. trachomatis* DNA in fresh testicular biopsies {#sec11}
--------------------------------------------------------------

Testicular biopsies (*n* = 18) were obtained from severely infertile men undergoing testicular sperm recovery. None of these patients reported previous diagnosis with an STI, including *C. trachomatis*. Thirteen men had a diagnosis of idiopathic infertility with severe oligo-azoospermia, and five azoospermic men had an identified cause including obstruction (cystic fibrosis, *n* = 2), Klinefelter syndrome (*n* = 1), Yq chromosome microdeletion (*n* = 1) and post-chemotherapy (*n* = 1) ([Table III](#TB3){ref-type="table"}). *C. trachomatis* DNA was found in 3 of the 18 specimens (16.7%): Patient 1, Patient 4 and Patient 5 ([Table III](#TB3){ref-type="table"}). Amplicons of all three specimens melted within 4°C of the positive control ([Table III](#TB3){ref-type="table"}). The gel electrophoresis shows all three specimens produced amplicons of similar size to the positive control ([Fig. 3](#f3){ref-type="fig"}). These tests assisted in confirming the detection of *C. trachomatis* DNA within the biopsies.

Detection of *C. trachomatis*-specific antibodies in human serum {#sec12}
----------------------------------------------------------------

Serum samples from the 18 patients were assessed for *C. trachomatis* serovar D- and E-specific IgG by dot blotting. Serum samples from three patients whose biopsies were PCR-positive showed seropositivity to one or both of the serovar: D and/or E ([Table III](#TB3){ref-type="table"}). Serum samples from eight other patients also showed seropositivity to one serovar ('+'), while two additional patients were serovar D and E seropositive ('++'). This gives a total of 13 positive samples: a *C. trachomatis*-specific antibody seropositivity rate of 72.2%. Examples of negative, single and double seropositive dot blots are shown in [Fig. 4](#f4){ref-type="fig"}a--f, along with immunocytochemistry of infected cell monolayers ([Fig. 4](#f4){ref-type="fig"}g and h). As the fresh biopsy cohort was small in this pilot study, it was not possible to show a correlation between PCR and serum positivity of patients.

###### 

Characteristics of patients providing fresh testicular biopsies

  **Participant**   **Clinical presentation**                  ***C. trachomatis* DNA in biopsies**   **PCR amplicon melt temperature**   ***C. trachomatis* antibody seropositivity in serum**
  ----------------- ------------------------------------------ -------------------------------------- ----------------------------------- -------------------------------------------------------
  C. trachomatis    N/A                                        Positive Control                       83.7                                N/A
  **Patient 1**     Azoospermia                                **+**                                  83.7                                \+
  Patient 2         Oligozoospermia                            \_                                     N/A                                 \+
  Patient 3         Cystic fibrosis                            \_                                     N/A                                 \+
  **Patient 4**     Azoospermia                                **+**                                  83.5                                \+
  **Patient 5**     Severe oligozoospermia, Y deletion         **+**                                  83.0                                ++
  Patient 6         Oligozoospermia                            \_                                     N/A                                 \_
  Patient 7         Klinefelter syndrome, undescended testis   \_                                     N/A                                 ++
  Patient 8         Azoospermia                                \_                                     N/A                                 \+
  Patient 9         Azoospermia                                \_                                     N/A                                 \_
  Patient 10        Azoospermia                                \_                                     N/A                                 \_
  Patient 11        Azoospermia                                \_                                     N/A                                 \+
  Patient 12        Azoospermia                                \_                                     N/A                                 \+
  Patient 13        Azoospermia                                \_                                     N/A                                 \_
  Patient 14        Cystic fibrosis                            \_                                     N/A                                 \_
  Patient 15        Azoospermia                                \_                                     N/A                                 \+
  Patient 16        Severe oligozoospermia                     \_                                     N/A                                 \+
  Patient 17        Post-chemotherapy                          \_                                     N/A                                 ++
  Patient 18        Azoospermia                                \_                                     N/A                                 \+

Bold text: Chlamydia positive patients.

Discussion {#sec13}
==========

Our findings demonstrate for the first time that replicating *C. trachomatis* is present in human testicular tissue and may be associated with moderate to severe spermatogenic impairment. We utilised highly specific DNA and protein markers to diagnose an unexpectedly high prevalence of chlamydial infection in two distinct populations of infertile men, who underwent either diagnostic (fixed) or therapeutic (fresh) biopsy. Furthermore, similarly high rates of detection (40--54%) were present in all of the major histological categories of spermatogenic failure represented in the fixed biopsies. These findings have profound implications for the study of the etiology of idiopathic male infertility and the pathogenesis of testicular chlamydial infection. There are also broader implications for clinical practice in terms of detection of infection in the testis and role for therapy.

These samples may represent a population that is enriched for chlamydial positivity, and the rate is most likely lower in the general population that includes reproductively healthy men, at least when conventional detection systems are used. Unsurprisingly, there was no difference in infection prevalence rates amongst histology types as many testicular insults lead to each of these histological patterns over the evolution of spermatogenic damage, culminating, for example, in the Sertoli cell only phenotype. While a causative role for chlamydial infection and the time course of damage cannot be assessed in the cross-sectional sampling approach, the data could potentially implicate chlamydial infection in damage to the seminiferous tubules.

The presence of *Chlamydia* within fixed biopsies was assessed by two distinct methods. The immunohistochemistry-positive samples were also PCR-positive, and there were no false-positive samples. In particular, the use of the active replication marker TC0500 indicates that at the time of biopsy, these patients had live *C. trachomatis* replicating within the testicles.

However, 50% of immunohistochemistry-negative fixed biopsy samples were PCR-positive. This may highlight the increased sensitivity of PCR compared to immunohistochemistry, as some samples may have a bacterial burden below the limit of immunohistochemistry detection. Alternatively, PCR will also identify DNA from dead *Chlamydia* ([@ref9]), whereas immunohistochemistry may only identify live *Chlamydia* within the intracellular inclusion structures produced during replication ([@ref1]). In these cases, infection may have been cleared by the host immune response or antibiotic therapy. The past *C. trachomatis* infections seem likely to have damaged the seminiferous tubules. Unfortunately, patient information for these archived samples was not available to investigate this further.

![**Detection of *C. trachomatis*-specific antibodies in serum from male-factor infertility patients.** *C. trachomatis* serovar E (Ctr E)- and serovar D (Ctr D)-loaded nitrocellulose membranes were probed with patient serum. Ctr D-infected HeLa cells were also probed with human serum as a negative control. Examples of these tests from patients with no Ctr-specific antibodies (Patient 16: **a**, **d**), Ctr D specific antibodies (Patient 1: **b**, **e**) and Ctr D- and Ctr E-specific antibodies (Patient 5: **c**, **f**) are shown along with immunocytochemistry of infected cell monolayers (Patient 16: **g** and Patient 5: **h**). Fluorescent images were captured using epifluorescent microscopy on ×40 magnification.](dez169f4){#f4}

The fresh biopsies were *C. trachomatis* PCR-positive in 3 of 18 cases, and of these 18 samples, 5 patients had conditions known to cause azoospermia. Normally, diagnosis of *C. trachomatis* is based on urine PCR. Both Patient 4 and Patient 5 had tested urine-negative; unfortunately, no result could be obtained for Patient 1. Taken together, the results indicate that upper reproductive tract infection may not shed into the urinary system or may do so only intermittently. Higher rates of detection are possible with semen analysis, including in an ART setting, highlighting the need for more robust chlamydial detection methods ([@ref18]; [@ref21]; [@ref4]). A more sensitive approach may include testing of testicular needle aspiration or open biopsy samples at the time of collection for sperm retrieval procedures. Given that PCR is utilised as a clinical tool for diagnosis of *Chlamydia* in other body sites, a testicular PCR assay may be a powerful instrument in future fertility evaluation protocols. Chlamydial screening of diagnostic and therapeutic testicular biopsies in male infertility patients could inform clinicians about the course of action required for patients and improve reproductive outcomes. Antibiotic therapy that eradicates testicular infection may improve sperm quality and improve reproductive outcomes ([@ref22]; [@ref14]). However, this also requires further investigation into the mechanisms of chlamydial pathophysiology, which has begun in a mouse model ([@ref22]; [@ref17]).

Additionally, as is already the case in public health practice for many STIs, once a diagnosis is made, an effort should be undertaken to screen and treat all sexual contacts. Transmission between partners may occur unknowingly, as the testicular infection may be asymptomatic and pose a risk to future fertility.

Serum samples matched to the fresh biopsies were assayed for the presence of *C. trachomatis*-specific antibodies. The long serum half-life of IgG confounds exact determination of when a chlamydial infection occurred and whether it is active ([@ref2]). The rate of *C. trachomatis*-specific antibody detection in serum in our study was at the high end of the range identified in literature, which varies widely between 0 and 90.3% depending on geographic and demographic factors, antibody type and testing material ([@ref7]; [@ref16]). The incidence is also likely higher in infertility cohorts than in the general population. However, it could be inferred that the seropositivity confirms the finding of *C. trachomatis* DNA within the fresh testicular biopsies, while seropositivity in the *C. trachomatis* DNA-negative patients is suggestive of a past infection.

Conclusion {#sec14}
==========

No evidence of human testicular chlamydial infection has been reported in the literature; therefore, this study describes the novel utilisation of PCR and immunohistochemistry to detect a previously unrecognised infection in nonobstructive azoospermic men. *Chlamydia* was detected in fixed diagnostic (40--54%) and fresh therapeutic (16.7%) testicular biopsies, and *Chlamydia*-specific antibodies were detected in serum samples from 72.2% of patients including all three patients who returned PCR-positive fresh biopsies. Although causality cannot be determined at this point, the detection of *Chlamydia* in otherwise asymptomatic infertile men is highly significant and will direct future studies on the mechanisms of damage by male chlamydial infection and approaches to the detection, prevention and treatment of a potentially preventable cause of human infertility.
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======================

###### 

Click here for additional data file.
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